Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nabriva Refreshes Lefamulin Strategy With New CEO, U.S. Office

This article was originally published in The Pink Sheet Daily

Executive Summary

The Vienna-based biotech looks to U.S. expertise to develop new mechanism-of-action antibacterial in go-it-alone strategy.

You may also be interested in...

Nabriva Wants To Try A Different Approach To Antibiotic Stewardship

Nabriva sees an opportunity for its Phase III antibiotic lefamulin to be used as a first-line agent against community-acquired bacterial pneumonia, rather than being held in reserve, because it targets pathogens that cause lung infections.

European Biotechs Mull Going To Market Without Big Pharma Partners

European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.

GSK’s First In Class Antibiotic Altabax Has Dosing, Price Advantage

GlaxoSmithKline's topical antibiotic Altabax (retapamulin) will offer a convenience benefit over other topical antibiotics, with less frequent dosing and less than half the treatment period

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts